PMID- 24797512
OWN - NLM
STAT- MEDLINE
DCOM- 20141229
LR  - 20211021
IS  - 1534-6307 (Electronic)
IS  - 1523-3774 (Linking)
VI  - 16
IP  - 6
DP  - 2014 Jun
TI  - Clinical relevance of beta(2)-glycoprotein-I plasma levels in antiphospholipid 
      syndrome (APS).
PG  - 424
LID - 10.1007/s11926-014-0424-9 [doi]
AB  - Antiphospholipid syndrome (APS) is characterized by the presence of 
      antiphospholipid (aPL) antibodies associated with thrombosis or pregnancy 
      morbidity. The antibodies mainly involved in this disorder are directed against 
      beta2-glycoprotein I (beta2-GPI). beta2-GPI plasma level is usually not reported in 
      studies on APS, because it is not regarded as relevant to the diagnosis and 
      prognosis of APS. Nevertheless its measurement may be important for understanding 
      the pathophysiology of the syndrome. This review summarizes available data from 
      the literature on plasma concentrations of beta2-GPI in patients with different 
      antibody profiles.
FAU - Banzato, Alessandra
AU  - Banzato A
AD  - Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Via 
      Giustiniani, 2, 35128, Padova, Italy, alessandra.banzato@unipd.it.
FAU - Pengo, Vittorio
AU  - Pengo V
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Rheumatol Rep
JT  - Current rheumatology reports
JID - 100888970
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (beta 2-Glycoprotein I)
SB  - IM
MH  - Antibodies, Antiphospholipid/blood
MH  - Antiphospholipid Syndrome/*blood/immunology
MH  - Humans
MH  - Thrombosis/blood/immunology
MH  - beta 2-Glycoprotein I/*blood/immunology
EDAT- 2014/05/07 06:00
MHDA- 2014/12/30 06:00
CRDT- 2014/05/07 06:00
PHST- 2014/05/07 06:00 [entrez]
PHST- 2014/05/07 06:00 [pubmed]
PHST- 2014/12/30 06:00 [medline]
AID - 10.1007/s11926-014-0424-9 [doi]
PST - ppublish
SO  - Curr Rheumatol Rep. 2014 Jun;16(6):424. doi: 10.1007/s11926-014-0424-9.